Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain embodiments, the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated with muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.

Abstract: Aspects of the disclosure are directed to an adaptive cache memory buffer register reassignment. In accordance with one aspect, the disclosure includes incrementing a write hit-miss state based on a write address validation state and a write data validation state; incrementing a read hit-miss state based on a read address validation state and a read data validation state; computing a net mode count based on the write hit-miss state and the read hit-miss state; comparing the net mode count to a mode threshold value to update a plurality of mode toggle states; and generating an adaptive cache memory buffer register reassignment based on the plurality of mode toggle states.

Abstract: An electronic device may have a plurality of defined life cycle stages and a one-time-programmable (OTP) memory comprising a plurality of life cycle bits, wherein respective bit patterns of the life cycle bits may correspond with respective life cycle stages of the defined life cycle stages. The electronic device may also have a boot code stored in read only memory and executable by a processor to receive a request to transition from a current life cycle stage to a next life cycle stage and, in response to the received request, automatically generate a bit pattern corresponding to the next life cycle stage of the plurality of defined life cycle stages and program the bit pattern corresponding to the next life cycle stage of the plurality of defined life cycle stages in the OTP memory during a time when the OTP memory is not user-accessible.

Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of post-capillary pulmonary hypertension (PcPH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PcPH-associated complications.

Abstract: An electronic device includes a transaction host, first and second peripherals, memory, an access control register, and first and second access controllers. The memory stores access control identifier management instructions, a first task related to the first peripheral, and a first bitmask indicating respective access settings for the first and second peripherals for performing the first task. The access control register includes a first access control identifier for the first peripheral and a second access control identifier for the second peripheral. The transaction host executes the access control identifier management instructions to program the first and second access control identifiers based on the first bitmask, and subsequently executes the first task. The first and second access controllers control access to the first and second peripherals, respectively, based on the respective first and second access control identifiers programmed based on the first bitmask.

Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain embodiments, the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated with muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.

Abstract: In certain aspects, the present disclosure relates to methods of treating systemic sclerosis (SSc) using T?RII antagonists comprising a heterologous domain and a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides methods for treating one or more complications of SSc, including interstitial lung disease (ILD), with T?RII antagonists of the present disclosure.

Abstract: The present disclosure relates to a process for producing levulinic acid from the technical lignin. The technical lignin is rich in lignin and ash and do not have any other use and usually incinerated as a waste management strategy. During the incineration process, the cellulose also gets burnt and wasted. In the present disclosure, there is provided an economical and environmentally friendly process to produce levulinic acid from the technical lignin by using a synergistic combination of catalysts for high yields and high titer with acid recycling in a cost-effective manner.

Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells.

Abstract: In certain aspects, the disclosure provides multispecific binders (e.g., ActRIIB:T?RII heteromultimers comprising an ActRIIB polypeptide and a T?RII polypeptide). In some embodiments, the disclosure provides for novel binders comprising a T?RII polypeptide and a heterologous portion. The disclosure further provides that such multispecific binders (e.g., ActRIIB:T?RII heteromultimer) may be used to treat various disorders or conditions.

Abstract: The present invention relates to a 2G-bioethanol industry waste modified bitumen composition comprising bitumen or asphalt binder or a petroleum vacuum residue, 2G-bioethanol industry waste lignin, an elasticity modifying agent, and a reactive component. The 2G-bioethanol industry waste modified bitumen composition is storage stable and having different applications like road pavement, roofing, adhesive, waterproofing etc. The present invention also provides a process of preparation of 2G-bioethanol industry waste modified bitumen composition comprising reactive component(s), elasticity modifying agent(s) and 2G bioethanol industry waste lignin.

Abstract: A cache circuit includes read address registers to store memory addresses of data blocks requested in recent memory read transactions in a memory circuit and write address registers to store memory addresses of the data blocks recently written to the memory circuit. The cache circuit also includes data registers for storing data blocks corresponding to select memory addresses stored in the read address registers and the write address registers based on a pattern of recent memory transactions. The selection of memory addresses for which corresponding data blocks are stored in the data registers is based on a mode count that may be dynamically determined based on the memory addresses accessed in the most recent memory transactions. The mode count depends on whether a requested data block is stored in the data registers and whether the memory address is stored in the read address registers or the write address registers.

Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells.

Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of pulmonary arterial hypertension, particularly treating, preventing or reducing the progression rate and/or severity of one or more pulmonary arterial hypertension associated complications.

Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.

Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.

Abstract: In part, the present disclosure relates methods for treating heterotopic ossification or one or more complications of heterotopic ossification. In particular, the disclosure provided methods for treating heterotopic ossification by administering to a patient in need thereof one or more TGF? antagonists, optionally in combination with one or more additional active agents or supportive therapies for treating heterotopic ossification. For example, in some embodiments, the disclosure provided methods for treating heterotopic ossifications by administering to a patient in need thereof an effective amount of a T?RII polypeptide.

Abstract: This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments, the ALK7-binding proteins inhibit or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.

Abstract: In part, the present disclosure relates methods for treating, preventing, or reducing the progression rate and/or severity of myelofibrosis or one or more complications of myelofibrosis (extramedullary hematopoiesis, splenomegaly, anemia, and fibrosis). In certain aspects, the disclosure provides ActRIIB antagonists for use in treating, preventing, or reducing the progression rate and/or severity of one or more complications associated with Janus kinase inhibitor therapy in a patient (e.g., anemia).

Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF3/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.